S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:XBIT

XBiotech Stock Forecast, Price & News

$13.21
+0.08 (+0.61 %)
(As of 10/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.00
$13.59
50-Day Range
$12.39
$16.40
52-Week Range
$12.20
$20.75
Volume78,967 shs
Average Volume85,497 shs
Market Capitalization$401.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
30 days | 90 days | 365 days | Advanced Chart
Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.


XBiotech logo

About XBiotech

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIT
Employees
91
Year Founded
N/A

Sales & Book Value

Annual Sales
$40,000.00
Price / Sales
10,032.33
Book Value
$11.91 per share

Profitability

Net Income
$-11.22 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$401.29 million
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

1054th out of 1,361 stocks

Pharmaceutical Preparations Industry

507th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What stocks does MarketBeat like better than XBiotech?

Wall Street analysts have given XBiotech a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but XBiotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for XBiotech
.

How were XBiotech's earnings last quarter?

XBiotech Inc. (NASDAQ:XBIT) announced its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $4.53 million for the quarter. XBiotech had a negative net margin of 60.47% and a negative trailing twelve-month return on equity of 3.45%.
View XBiotech's earnings history
.

How has XBiotech's stock been impacted by COVID-19?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBIT shares have increased by 23.2% and is now trading at $13.21.
View which stocks have been most impacted by COVID-19
.

How often does XBiotech pay dividends? What is the dividend yield for XBiotech?

XBiotech announced a dividend on Tuesday, July 6th. Stockholders of record on Friday, July 16th will be paid a dividend of $2.50 per share on Friday, July 23rd. The ex-dividend date is Thursday, July 15th.
View XBiotech's dividend history
.

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • John Simard, Chairman, President & Chief Executive Officer
  • Ashley Otero, Vice President-Clinical Operations
  • Queena Han, Secretary, VP-Finance & Human Resources
  • Sushma Shivaswamy, Chief Scientific Officer
  • Mark Ziats, Medical Director

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech CEO John Simard on Glassdoor.com. John Simard has an approval rating of 58% among XBiotech's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), The Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Square (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $13.21.

How much money does XBiotech make?

XBiotech has a market capitalization of $401.29 million and generates $40,000.00 in revenue each year.

How many employees does XBiotech have?

XBiotech employs 91 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

Where are XBiotech's headquarters?

XBiotech is headquartered at 5217 Winnebago Ln, AUSTIN TX, 78744.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at (512) 386-2900 or via email at [email protected].


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.